We aim to create a lasting and meaningful impact on patients suffering from cardiac conditions.
Cardiovascular diseases are a major burden and the first cause of death globally.
18+
Millions
deaths/year
85%
caused by myocardial infarction
& stroke
300
millions Disability-adjusted
life years (DALY)
We unlock the potential of immunotherapies to reshape the future of Cardiovascular care.
Our revolution
We aim to drastically reduce the burden of cardiovascular diseases by providing early-stage treatment to patients, thereby mitigating the damage inflicted to the heart.
We designed a first in class monoclonal antibody that specifically targets the immune system to prevent cardiac damage in ischemic cardiovascular diseases.
Polygon emerges from cutting-edge academic research. The project is led by three co-founders with complementary backgrounds, all geared up to bring innovation from bench to patients' bed in a fresh, bold and committed approach.
Visit us
paris - headquarter
26 Rue LAFFITTE
75009 paris
France
paris - r&d office
56 rue leblanc
75015 Paris
France
Follow us
© 2024 POLYGON Therapeutics, SAS
